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The “Will this trial change my practice?” 
sessions at PCR
The aim of the article is to capture the session at EuroPCR 2015, 
communicate the analysis of the trialists, and report the views 
expressed in the interactive discussion. 
Introduction to the session
Bioresorbable stents (BRS) have been described as the fourth 
revolution in interventional cardiology. ABSORB II is the first 
randomised controlled clinical trial (RCT) comparing an everoli-
mus-eluting BRS with a second-generation everolimus-eluting 
permanent metallic stent (DES)1. A dedicated interactive EuroPCR 
session subjected this study to focused scrutiny with the help of 
facilitators consisting of Ibrahim Al-Rashdan, Robert Byrne, 
Robert-Jan van Geuns, Thomas Pilgrim, and Peter Jüni. An initial 
poll of the audience indicated that the majority did not currently 
use BRS in their daily practice. An introduction and overview of 
the session was given by Robert Byrne who explained that the 
trial data would be evaluated and discussed together with a case 
study illustrative of some of the issues surrounding this novel 
platform which would be presented by Robert-Jan van Geuns: 
a patient with stable angina and ischaemia on non-invasive evalu-
ation who had a BRS deployed in a severe stenosis within a calci-
fied right coronary artery following rotational atherectomy. The 
patient was ineligible for ABSORB II based on the strict entry cri-
teria but nevertheless was treated with BRS and entered into the 
ABSORB-EXPAND registry.
Do we need a change in practice?
Each iteration of permanent mechanical platform to treat ischae-
mic coronary stenosis has brought with it advantages as well as 
disadvantages including restenosis, neoatherosclerosis and stent 
thrombosis. The limitations of these platforms have driven the 
development of a drug-eluting resorbable platform that temporar-
ily scaffolds a lesion during the phase of healing following implan-
tation and then resorbs, leaving no residual material or nidus for 
stent thrombosis. Such a platform if efficacious and safe would be 
desirable.
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Second-generation DES are currently the standard platform 
used for the majority of coronary lesions around the world. Their 
improved safety profile, ease of deliverability and data with 
millions of patient years of experience raises the bar for fur-
ther device improvement to a high level. BRS is an innovative 
device that has the potential to change practice. Although cur-
rently use is limited, with approximately 100,000 patients hav-
ing been treated to date according to the manufacturers, their 
use is increasing, and thus this first randomised trial comparing 
it to contemporary DES gives the interventional community an 
opportunity for reflection.
Background
Robert Byrne opened with an overview of the trial design, origi-
nally published in 20122. The ABSORB II is an ongoing RCT of 
patients recruited from European and New Zealand centres with 2:1 
enrolment (BRS:DES), allocation concealment, event adjudication 
blinding and intention-to-treat analysis. The primary endpoint, for 
which it is adequately powered, includes angiographically deter-
mined nitrate-inducible vasomotion of the target lesion segment 
at 36 months. Secondary endpoints include clinical (patient and 
device-orientated) events also at 36 months. In particular, patient-
related outcome measures in the form of angina evaluation with 
the validated Seattle Angina Questionnaire tool as well as non-
invasive ETT evaluation were used. As the trial data were analysed 
at interim stages of six and 12 months, these recently published 
data along with the case illustration formed the basis of the ensu-
ing discussion.
Robert-Jan van Geuns then continued with the case presentation 
of BRS. This was implanted into the distal RCA of a female patient 
with stable angina and ischaemia on non-invasive evaluation who 
was deemed not suitable for the ABSORB II RCT due to calcifi-
cation and who was entered into a prospective registry. This case 
was illustrative of some of the issues surrounding the technology 
and inclusion of patients into the study and real-world use. For the 
ABSORB II RCT the entry criteria were restrictive and sought to 
include only simple coronary stenotic lesions: one or two de novo 
lesions in different vessels, no heavy calcification, <48 mm lesion 
length, 2.25-3.8 mm diameter and successful predilatation (mean-
ing a residual stenosis of <40%), and no use of adjunctive technol-
ogy suggestive of a complex lesion such as rotational atherectomy 
and cutting balloon. Robert-Jan van Geuns went on to say that 
those not fulfilling the criteria in full but still considered eligible for 
a BRS are typically entered, and should be entered, into a prospec-
tive registry such as ABSORB- EXPAND or EXTEND. A further 
point was made that, if aggressive lesion preparation, as currently 
advocated by manufacturers, is adhered to, then even those in the 
registry have similar clinical outcomes to those of contemporary 
DES platforms.
Ibrahim Al-Rashdan, with reference to the case, pointed out an 
opposing view that the use of BRS whether in a trial or registry was 
inappropriate due to the heavy calcium burden and challenge of 
device trackability in such vessels.
Robert Byrne posed a practical question regarding whether, once 
a decision to deploy a BRS has been made, angiographic confirma-
tion of scaffold expansion was sufficient or whether OCT was man-
datory. The group confirmed that liberal use of OCT was best after 
deployment but that its use was not mandatory.
Thomas Pilgrim painted the background. There are currently 
sixteen products that have been developed, and these can be sepa-
rated in broad terms into BRS made of a magnesium alloy and 
those made of PLLA. Several of these platforms elute a drug active 
against restenosis. To maintain comparable radial strength, their 
strut thickness is roughly double that of current metallic stents, 
making them bulky compared to DES. Their main appeal is their 
intrinsic resorbability over time. There are further potential physi-
ological benefits that include improved vasomotion (both physi-
ologically and pharmacologically induced), improved pulsatility 
(only demonstrated in porcine models so far), late lumen enlarge-
ment, and vulnerable plaque sealing (leading to the so-called 
“golden tube” on OCT). These encouraging parameters, however, 
need to translate into clinical benefit before being accepted as 
indicators of efficacy.
With this in mind, the latest registry data were summarised. 
ABSORB-EXTEND (n=512) showed a respectable late lumen loss 
of <0.5 mm, mortality of 0.5% and infarction of 2.9%, suggesting 
equivalent efficacy to contemporary DES3. GHOST-EU is the larg-
est registry to date (n=1,189) with 25% of lesions being bifurca-
tions, reporting an overall 2.1% rate of definite or probable stent 
thrombosis4.
This background raises questions over the specific clinical set-
tings best suited to BRS, whether strut thickness can be decreased 
further, and non-inferiority over current latest-generation drug-
eluting stents in terms of efficacy and, crucially, the safety of 
this platform. Large-scale randomised trials formed the consen-
sus view of the group as to how best to resolve these questions, 
ABSORB II being the first of these and ABSORB III and IV due 
to follow on thereafter. ABSORB III is a larger RCT including 
2,000 patients and more complex lesions (but still excluding cal-
cified stenoses, as well as acute and chronic occlusions) with 
a similar surrogate non-clinical primary endpoint. ABSORB IV 
will include 3,000 patients and use angina and quality of life met-
rics as its primary endpoint as well as including cost-effectiveness 
analyses5,6.
Trial analysis
Robert Byrne having given an overview, Peter Jüni provided 
an in-depth analysis of the study. As mentioned previously, the 
design of ABSORB II is that of a prospective randomised con-
trolled clinical trial with 2:1 enrolment (BRS:DES), allocation 
concealment, patient blinding (although it was noted that 35 sub-
jects in the BRS arm and five in the DES arm became unblinded), 
independent endpoint adjudication with blinding and an inten-
tion-to-treat analysis. The study was industry funded but with 
an independent academic steering group. The involvement of 
industry was raised as a concern as was the number of subjects 
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unblinded. Although it is challenging to maintain a blinded study, 
it was posited that this should be the aim, particularly where end-
points can be affected by subjective interpretation. Nonetheless, 
the near complete follow-up of >98% (with five subjects lost in 
the BRS arm and two in the DES arm) is a testament to the high-
quality conduct and rigour of the trialists and compares very well 
against RCTs in other disciplines where follow-up rates of circa 
80% are commonplace.
The study is powered for superiority of BRS at three years 
(36 months) on the primary outcome of angiographically deter-
mined nitrate-induced vasomotion, and non-inferiority for in-stent 
late loss. All other endpoints are secondary and thus exploratory 
only. These endpoints include clinical (patient and device-orien-
tated) events at 36 months and patient-related outcome measures 
(PROMS) in the form of angina evaluation with the Seattle Angina 
Questionnaire. Given the residual angina experienced by many fol-
lowing conventional metallic stent treatment, despite procedural 
success and no major adverse event, this is a potentially important 
endpoint.
The patient and lesion characteristics were described and dem-
onstrated no significant differences between BRS and DES. The 
cohort is slightly younger than is typical of general interventional 
practice with a mean age of 61.5 (SD 10) and 60.9 (SD 10), respec-
tively. The predominant presentation was stable angina but there 
were 20% with unstable angina, and it was posited that these should 
have been excluded. The lesions treated were predominantly inter-
mediate (AHA class B1 and B2 lesions >96%) with almost no com-
plex lesions (AHA class C).
Differences, however, were apparent with the procedural charac-
teristics. The BRS group used lower mean inflation pressures com-
pared to the DES group (14.23 vs. 15.03 atm). Although the acute 
device and procedural success recorded did not differ, it was noted 
that the difference in inflation pressure was associated with a real 
difference in angiographic residual vessel diameter 2.64 mm (SD 
0.4) vs. 2.8 mm (SD 0.3) and minimum luminal diameter 2.22 mm 
(SD 0.3) vs. 2.5 mm (SD 0.3).
The outcomes were subjected to scrutiny, in particular the use 
of PROMS. These have been used in other fields for many years 
and are now making their way into cardiovascular device tri-
als. Self-reported angina was evaluated using the Seattle Angina 
Questionnaire (SAQ) tool. This consists of several domains - physi-
cal limitation, angina stability, medication use, treatment satisfac-
tion, and disease perception. Although a difference was suggested 
by ETT data indicating ischaemic changes in favour of the BRS 
group (4.3% vs. 17.2%, p=0.05), there were no differences in SAQ-
reported angina at 12 months. However, a post hoc exploratory 
analysis, excluding the first seven days following device deploy-
ment, of first occurrence and duration of recurrent or worsening 
angina was recorded. This analysis, in favour of BRS (16.4% vs. 
25.6%, p=0.015), suggests that the cumulative rate of angina may 
be a better tool than examining angina at an isolated time point, and 
thus challenges the way we currently collect such data. This there-
fore warrants further investigation.
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Figure 1. Cardiac death, all myocardial infarction, and clinically 
indicated target lesion revascularisation (major adverse cardiac 
events). Figure reproduced from the PCR Trials Book 
(© 2015 Europa Digital & Publishing).
For harder clinical outcomes (composite of cardiac death, target 
vessel MI and clinically indicated target vessel revascularisation) 
(Figure 1), there was a trend towards more infarction in the BRS 
group (4.2% vs. 1.2%, p=0.07) and minimally more stent thrombo-
sis (three patients [0.6%] vs. none, p=1.0). This tendency, reflected 
by greater troponin elevation in the BRS group, probably does not 
represent a real concern as examination of the device and proce-
dure-related events recorded using contemporary definitions of 
periprocedural MI showed no difference.
Peter Jüni ended by reiterating the importance of blinded patients, 
especially with self-reported outcomes and excluding those who 
are unblinded. The question of the appropriateness of angiographic 
TLR as a performance measure for BRS was also raised on account 
of potential improvement in vasomotion properties.
Session discussion (participants and 
facilitators)
Ibrahim Al-Rashdan opened the discussion. It was felt that, despite 
ABSORB II, the signal of stent thrombosis in the largest contem-
poraneous registry had necessarily reduced use, and a 15-20% mar-
ket penetration ceiling for BRS was quoted. Importantly, the study 
interpretation was still supportive of BRS use within strict limits. 
Overall, the consensus was that a measure of benefit over a more 
appropriate length of time in a larger population representing daily 
practice was required.
One member of the audience agreed with the facilitators that BRS 
remains investigational. It was pointed out that operators needed to 
remember that BRS is more technically challenging to deploy than 
DES. This view was reinforced by Peter Jüni, with a reminder that 
the influence of the operator would be a major factor in the effi-
cacy and safety of a device whenever a material was unforgiving 
as seems to be the case with BRS. A counter point made by Robert-
Jan van Geuns was that, given the fact that we are still learning 
from our experience of the device, these concerns should not pre-
vent continued use as part of registry or trial programmes. The use 
of interim analysis was questioned by Robert Byrne in terms of the 
validity of the final trial report at 36 months. Peter Jüni clarified 
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that the data thus far were explorative and so would not endanger 
the final primary endpoint.
Ibrahim Al-Rashdan reminded the participants that there was 
a big difference between the real world and that of ABSORB II. 
Lesion preparation was key and, in particular, avoiding heavily cal-
cified regions, keeping in mind that multiple projections were fre-
quently necessary to determine this. Indeed Robert-Jan van Geuns 
had explained that the case study presented at the start was a com-
plex lesion not eligible for ABSORB II and entered into a regis-
try. Clinical and angiographic follow-up of the case revealed no 
adverse events at 12 months with further progression of more distal 
disease.
The challenges of device deployment are reflected in the continued 
evolution of the procedural implant recommendations, even follow-
ing on from those in ABSORB II. More aggressive predilatation with 
a non-compliant balloon and 1:1 balloon:artery ratio is now advised. 
Cutting balloons and rotablation are now encouraged. A previously 
recommended overlap of 2-4 mm has now been superseded by a rec-
ommendation for no overlap. Post-dilatation is now highly recom-
mended and mandatory if there is >10% residual stenosis.
Major views expressed regarding BRS use
– Lesion selection and preparation using the latest recommenda-
tions is paramount.
– ABSORB II interim data are exploratory only; longer-term fol-
low-up and larger population experience are required.
– Continued use is justified only as part of a trial or established reg-
istry programme.
– Stent thrombosis, once the data on MI were analysed, did not 
indicate a concern.
– The evaluation of angina as an efficacy endpoint for these coro-
nary devices is still evolving, and the relevance of new measures 
is not entirely clear.
Final audience poll
For the minority who use BRS, the trial experience thus far would 
influence them to adhere to the latest technical recommendations. 
However, a poll of the majority not implanting revealed a consen-
sus that the data were not sufficient to alter their practice. In the 
light of this, the final results of ABSORB II as well as the larger 
ABSORB III and IV are eagerly awaited.
Conclusion
Ibrahim Al-Rashdan concluded the session by reiterating the impor-
tance of sticking to rigorous selection criteria and the latest recom-
mended implantation technique for BRS at all times. A signal of stent 
thrombosis, while not substantiated in this study thus far, may have 
occurred in registry data due to suboptimal implantation techniques, 
particularly in complex lesion subsets. The results of PROMS as well 
as post hoc angina burden analysis and what they mean should be 
interpreted with caution as far as BRS are concerned.
Nevertheless, the BRS device and concept remain exciting and, 
although currently there are no overwhelming data to support 
real-world practice change, “we must not throw the baby out with 
the bathwater”.
Summary box
Major arguments for a change in practice
– Residual angina can affect a significant proportion of patients 
treated with conventional stent technology despite good pro-
cedural and major clinical outcome. Vascular scaffolds may 
lead to reduced angina burden.
– Equivalent MACE between DES and BRS.
– No signal of stent thrombosis if selection criteria and recom-
mended implantation technique used.
Major arguments against change
– ABSORB II has not reported final results and so the cur-
rently released interim data on secondary endpoints at six 
and 12 months are exploratory only. Ultimately, the primary 
endpoint will be a non-clinical surrogate of angiographically 
determined nitrate-induced vasodilatation at 36 months.
– Real-world adherence to a more rigorous selection and implan-
tation for current BRS may be challenging. Stent thrombosis 
in observational series may relate more to the implantation 
technique than to the scaffold. Nevertheless, much greater 
observational data are needed to prove safety.
– Interpretation of angina evaluation as an efficacy outcome in 
coronary device trials is evolving. Angina evaluation so far 
suggests no benefit, and exploratory analysis of total angina 
burden is post hoc.
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